Chinese Vaccine Ad5-Ncov Shows High Antibody Levels at Russian Trial

Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, Reuters reports, according to the Interfax news agency.

Ad5-nCoV is a candidate vaccine co-developed by CanSino Biologics and a Chinese military-backed research unit.